You can buy or sell Glaukos and other stocks, options, ETFs, and crypto commission-free!
Glaukos Corporation, also called Glaukos, is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. Read More The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
San Clemente, California
52 Week High
52 Week Low
Yahoo FinanceMar 15
Pivotal Trial Results for Glaukos’ iStent inject® Published in Leading Ophthalmic Journal
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Study Published in Ophthalmology Demonstrates Significant, Sustained Clinical Benefit and Confirms Favorable Safety Profile for Next-Generation Device Approved by FDA in June 2018 Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that the U.S. Investiga...
Glaukos Technologies Featured in Numerous Presentations at 2019 American Glaucoma Society Meeting
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be featured in various presentations at the American Glaucoma Society (AGS) Annual Meeting on March 14-17, 2019 at the Marriott Marquis Hotel in San Francisco. Glaukos is spons...
Yahoo FinanceMar 13
When Should You Buy Glaukos Corporation (NYSE:GKOS)?
Glaukos Corporation (NYSE:GKOS), which is in the medical equipment business, and is based in United States, saw a significant share price rise of over 20% in the past couple of months on the NYSE. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price.
Expected May 8, After Hours